The FDA's drug approvals database has recorded a supplement to new drug application 215866, held by Eli Lilly for Mounjaro (tirzepatide). The record does not state what the supplement covers; supplements to an NDA can concern labelling, manufacturing, dosing or a new indication.
Until the content is published, it should not be read as a new indication or a safety change. Prescribers should look for the updated label on the FDA site before acting on any report of a change. In India, tirzepatide's approved uses are those set by CDSCO, which this US action does not alter.
- Make no change to tirzepatide prescribing on the basis of this notice alone.
- Check the updated FDA label once published to see what the supplement covers.
- Follow the CDSCO-approved indications for tirzepatide in India.
Why it matters
Supplements to widely used drugs sometimes carry label changes, so the published label is worth checking.
Don't overread it
A licence supplement is not, by itself, a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free